Potential Candidates for Focal Therapy in Prostate Cancer in the Era of Magnetic Resonance Imaging-targeted Biopsy: A Large Multicenter Cohort Study
| Autor: | Verena Lieb, Martin Drerup, Johannes Bruendl, Fabian Siegel, Angelika Borkowetz, Tobias B Jordan, Jost von Hardenberg, Kira Kornienko, Hannes Cash, Kasra Taymoorian, Thomas Höfner, Manuela A Hoffmann, Roman Ganzer, Martin Schostak, Niklas Westhoff |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty Prostate biopsy Urology Biopsy 030232 urology & nephrology Cohort Studies 03 medical and health sciences Prostate cancer 0302 clinical medicine Prostate Medicine Humans medicine.diagnostic_test business.industry Prostatic Neoplasms Magnetic resonance imaging Prostate-Specific Antigen medicine.disease Magnetic Resonance Imaging medicine.anatomical_structure 030220 oncology & carcinogenesis Prostate neoplasm Radiology business Energy source Cohort study |
| Zdroj: | European urology focus. 7(5) |
| ISSN: | 2405-4569 |
| Popis: | Focal therapy (FT) with its favorable side-effect profile represents an option between active surveillance and traditional whole-gland treatment in localized prostate cancer (PCa). Consensus statements recommend eligibility criteria based on magnetic resonance imaging (MRI)-targeted and systematic combination biopsy.To estimate the future potential of FT by analyzing the number of men eligible for FT among all men with biopsy-proven PCa and to judge the potential of different energy sources.Consensus criteria on FT were analyzed. Patients with biopsy-proven PCa from six tertiary referral hospitals and one outpatient practice in Germany had received a software-based combination biopsy. Men with Prostate Imaging Reporting and Data System (PI-RADS) ≥3 lesions based on PI-RADS v2 were included.Patients were analyzed for potential treatment by FT and hemiablation. MRI lesions were mapped according to prostatic zones.In total, 2371 patients were analyzed. According to consensus criteria (biopsy-proven unifocal lesion of International Society of Urological Pathology [ISUP] grade group ≤2, prostate-specific antigen [PSA] ≤15ng/mL, and life expectancy10yr), 303 patients (12.8%; ISUP 1: n=148 [6.2%]; ISUP 2: n=155 [6.5%]) were potential candidates for FT. A maximum PSA level of10ng/mL would exclude further 60 (2.5%) of these men. The eligibility for hemiablation is slightly higher (16.2%). Unifocal lesions (n=288) were equally distributed within the prostate (anteriorly [31%], apically [29%], and dorsally [36%]).With adherence to consensus statements, only a minority of PCa patients present as potential candidates for FT. Distribution of tumor localization suggests the need for different energy modalities to warrant an optimal FT treatment.We analyzed how many men who receive a magnetic resonance imaging-targeted and systematic prostate biopsy are candidates for the experimental focal therapy of the prostate. When following expert recommendations, only a small number of men are potential candidates for this alternative treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect